Biocon Biologics Insulins Facility in Malaysia Receives EU GMP Certification

"Biocon Biologics' integrated insulins manufacturing facility in Malaysia is approved by the European Medicines Agency following a site inspection in July 2022. The Company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland. This approval reflects the agency's determination that the manufacturing facilities for Drug Substances, Drug Products, Insulin Delivery Device Assembly, as well as Secondary Packaging and Warehousing areas are in compliance with the guidelines of Good Manufacturing Practices. This certificate enables the Company to continue addressing the needs of people with diabetes in the EU who require Insulin Glargine and Insulin Aspart.

"Biocon Biologics remains committed to the global standards of Quality and Compliance." - Company Spokesperson.

Shares of Biocon Limited was last trading in BSE at Rs. 268.70 as compared to the previous close of Rs. 270.50. The total number of shares traded during the day was 31507 in over 917 trades.

The stock hit an intraday high of Rs. 271.35 and intraday low of 266.60. The net turnover during the day was Rs. 8475805.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics InsulinManufacturingFacility Malaysia Approval